For localized information and support, would you like to switch to your country-specific website for {0}?
Key takeaways
- Around 250 participants from 35 countries, including 50 world-renowned faculty members, convened in Basel, Switzerland
- During the two-day event, diagnostic and therapeutic solutions to manage the different stages of the CKM syndrome were discussed
- Focus topics were:
- Cardiac biomarkers, such as hs-cTn and NT-proBNP, remain central to diagnosis and management in later CKM stages
- Diabetes, chronic kidney disease and obesity represent earlier CKM stages, where screening and intervention could prevent disease progression
- The liver should be part of integrated CKM management, as cardiometabolic risk factors put individuals at risk of advanced fibrosis
The 14th proCardio 2026 took place in Basel, Switzerland
On 7 and 8 October 2026, the 14th proCardio forum returned to the Roche headquarters in Basel, Switzerland. It welcomed around 250 participants from 35 countries, including 50 world-renowned faculty members, under the chairmanship of Prof. James L. Januzzi and Prof. Pam R. Taub.
Building on the cardiovascular-kidney-metabolic (CKM) interconnection, this edition explored the value of biomarkers, therapeutics, digital and POC solutions along the stages of the CKM syndrome. The programme followed the stages backwards, from clinical cardiovascular disease to the earliest risk factors, shifting the focus from treatment to prevention.
Besides presentations on the latest scientific advancements, time was dedicated to extensive discussions. Two interactive sessions, Turning Tables and Find the Expert, gave attendees the chance to engage directly with the faculty on implementation topics, and the meeting closed with a panel discussion on how CKM research and lived experience can shape health policy.
What was covered at proCardio in 2026?
Day 1 opened with clinical cardiovascular disease. Topics included the next-generation high-sensitivity troponin T assay and the TSIX study programme, digital tools for chest pain triage and the fifth universal definition of myocardial infarction. In heart failure, the faculty discussed strategies for earlier diagnosis in primary care and the rapid implementation of guideline-directed medical therapy based on STRONG-HF.
The focus then moved to subclinical disease: NT-proBNP-based screening of people with diabetes, comparing the STRONG-DM and TARTAN-HF studies, urine albumin-creatinine ratio as cardio-kidney risk marker, and precision imaging and AI to detect silent atherosclerosis.
Day 2 covered the earlier CKM stages. Sessions explored troponin interpretation in chronic kidney disease, multi-organ risk assessment in diabetes, new approaches to blood pressure monitoring, and obesity beyond BMI, including the case for adding the liver to integrated CKM care. The programme closed with a focus on prevention, with presentations on inflammation (hsCRP) and lipoprotein(a), before the policy panel.
Interested in more insights from attendees of the event? Watch the highlight video from proCardio 2026!
Explore more
Interested in proCardio?
Register your interest for proCardio 2026 updates and you will receive updates about the event, including the proCardio 2026 final meeting report, and the event highlight video.
By subscribing, you will also gain access to CarDiaLogue, our premier digital hub for healthcare professionals. Stay at the forefront of the field with expert insights and curated content dedicated to cardiometabolic disease management.